Get the Stockscreener App
7.43
17.75%
1.12
After Hours:
7.44
0.01
+0.13%
Nuvectis Pharma Inc stock is traded at $7.43, with a volume of 163.16K.
It is up +17.75% in the last 24 hours and up +21.80% over the past month.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
See More
Previous Close:
$6.31
Open:
$6.22
24h Volume:
163.16K
Relative Volume:
1.39
Market Cap:
$138.59M
Revenue:
-
Net Income/Loss:
$-22.38M
P/E Ratio:
-4.7935
EPS:
-1.55
Net Cash Flow:
$-15.54M
1W Performance:
-5.59%
1M Performance:
+21.80%
6M Performance:
-8.72%
1Y Performance:
-22.28%
1-Day Range:
$6.00
$7.48
1-Week Range:
$6.00
$8.2399
52-Week Range:
$5.85
$12.10
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Name
Nuvectis Pharma Inc
Sector
Industry
Phone
360-837-7232
Address
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-13-22 | Initiated | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Stock (NVCT) Latest News
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire
Trend Tracker for (NVCT) - Stock Traders Daily
Nuvectis Pharma's NXP900 Shows Promise in NSCLC Treatment, NXP800 Data Update Anticipated - Vancity Buzz
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update - StockTitan
NVCTNuvectis Pharma, Inc. Latest Stock News & Market Updates - StockTitan
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times
Nuvectis Pharma Announces Upcoming Presentations for NXP900 - GlobeNewswire
Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - The Manila Times
Learn to Evaluate (NVCT) using the Charts - Stock Traders Daily
Here's Why We're Watching Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation - Yahoo Finance
(NVCT) Trading Advice - Stock Traders Daily
Industry Update: 3 Exciting Precision Oncology Players to Watch - openPR
A new trading data show Nuvalent Inc (NUVL) is showing positive returns. - SETE News
What's Going On With Nuvve Stock? - Benzinga
Rhumbline Advisers Has $3.18 Million Position in NVE Co. (NASDAQ:NVEC) - Defense World
ESMO where that came from: Nuvalent bags $500M on hot early data - BioWorld Online
SEC Form 424B5 filed by Nuvalent Inc. - Quantisnow
Why Nuvalent (NUVL) Shares Are Down 6% Today - Benzinga
Nuvalent: Likely Approvals Coming Up Do Not Justify This Valuation (NASDAQ:NUVL) - Seeking Alpha
Nuvalent Inc Inc. (NUVL) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Biopharma co Nuvalent slips after upsized $500 mln stock offering priced - XM
Nuvalent 5M share Secondary priced at $100.00 - TipRanks
Nuvalent announces pricing of $500M upsized stock offering - MSN
Nuvalent Earns Relative Strength Rating Upgrade - Investor's Business Daily
Nuvoco Vistas Corporation Block Deal | 1.2% equity worth ₹158 crore changes hands - CNBCTV18
Nuvalent (NASDAQ:NUVL) Reaches New 1-Year High Following Analyst Upgrade - Defense World
Nuvoco Vistas sees large block trade: 45 lakh shares worth ₹158 crore - Business Upturn
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock - PR Newswire
Nuvalent stock outlook positive amid key questions on trial enrollment and FDA approval strategy - Investing.com India
Nuvectis Pharma’s NXP900 Shows Promise in NSCLC Treatment, New Report Suggests - Vancity Buzz
Monitoring Nuvalent Inc (NUVL) after recent insider movements - Knox Daily
An analyst sees good growth prospects for Nuvation Bio Inc (NUVB) - SETE News
Company’s Banking Shares: Up -97.40% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle
Nuvalent gains after brokerages raise PT on promising cancer therapy data - XM
PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch - BioSpace
Nuvalent Shares Gain on Cancer Drug Trial Updates - MarketWatch
Nuvalent price target raised to $132 from $102 at BMO Capital - TipRanks
Nuvalent announces $350M offering of Class A common stock - TipRanks
Nuvalent Announces Public Offering of Common Stock - Yahoo Finance
NUVVE ANNOUNCES 1-FOR-10 REVERSE STOCK SPLIT - Nasdaq
Nuvalent (NASDAQ:NUVL) Stock Price Down 3.9% on Insider Selling - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Stock Price Down 8.5% - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Trading Down 8.5% - Defense World
Nuvectis’ NXP800 gains FDA ODD for cancer treatment - MSN
Insider Buyers Lose Additional US$46k As Nuvectis Pharma Dips To US$115m - Simply Wall St
When (NVCT) Moves Investors should Listen - Stock Traders Daily
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Nuvectis Pharma Inc (NVCT) Becoming More Attractive for Investors - Knox Daily
Is Nuvectis Pharma Inc (NVCT) worth investing in despite its overvalued state? - US Post News
The time has not yet come to remove your chips from the table: Nuvectis Pharma Inc (NVCT) - SETE News
Nuvectis Pharma Inc Stock (NVCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvectis Pharma Inc Stock (NVCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BENTSUR RON | Chairman & CEO |
May 10 '24 |
Buy |
6.40 |
2,000 |
12,800 |
3,244,484 |
| Poradosu Enrique | Chief Science & Business Off |
May 10 '24 |
Buy |
6.29 |
500 |
3,145 |
1,504,319 |
| Shemesh Shay | Chief Dev. & Ops. Officer |
May 10 '24 |
Buy |
6.32 |
1,113 |
7,034 |
1,493,068 |
| BENTSUR RON | Chairman & CEO |
Mar 18 '24 |
Buy |
10.29 |
5,000 |
51,450 |
3,242,484 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):